proarrhythmia


Also found in: Wikipedia.

proarrhythmia

/pro·ar·rhyth·mia/ (pro″ah-rith´me-ah) cardiac arrhythmia that is either drug-induced or drug-aggravated.proarryth´mic

proarrhythmia

Cardiology A drug-related arrhythmia, seen in 4–6% of Pts treated for V tach or V fib, especially in Pts treated with digitalis & diuretics, ↓ left ventricular function, longer pretreatment Q-T intervals Pathogenesis Altered reentry substrate and early after depolarization. See Arrhythmia.

proarrhythmia

(prō-ă-rĭth′mē-ă)
An arrhythmia that is stimulated, provoked, or worsened by drug therapy.
proarrhythmic, adjective
References in periodicals archive ?
Azithromycin-induced proarrhythmia and cardiovascular death.
In the past 2 decades, many attempts that were made to suppress symptomatic frequent VPCs with antiarrhythmic drugs (AADs) resulted in proarrhythmia, cardiac function inhibition, and a failure to improve survival.
The endo-before -epi surgical hybrid AF ablation procedure is defined by a comprehensive endovascular approach preceding and guiding the epicardial ablation coupled with an extensive epicardial posterior wall ablation to replace the posterior "box lesion" and mitral isthmus lines and their resulting proarrhythmia.
Envigo will develop and internally validate five to seven ion channel In vitro tests for measuring cardiac risk potential--ahead of the Comprehensive In Vitro Proarrhythmia Assay (CiPA) recommendations expected at the end of this year.
Improved cardiac safety assays using iPS cardiomyocytes are a vital part of the FDA's Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative.
The companies said the development of cardiac safety assays using iPS cardiomyocytes is key to the FDAs Comprehensive in vitro Proarrhythmia Assay (CiPA) program an initiative in which both companies are taking part.
Oftentimes, these specific PSVTs are difficult to treat medically due to therapy refractoriness and associated side effects, proarrhythmia, cost, and inconvenience.
To address this, the FDA proposed a new paradigm labeled the "Comprehensive In Vitro Proarrhythmia Assay" to assess the cardiac safety of new or existing drugs in phase 1 studies.
The risk of proarrhythmia is present with antiarrhythmic agents, and clinicians are cautioned to assess risk versus benefit before starting any of the agents.
On the other hand, there is sufficient nonclinical and clinical epidemiological evidence to suggest that shortening of QT interval may be a potential harbinger of proarrhythmia [32].
Beta-blockers can also be implicated if abruptly withdrawn preoperatively, leading to a postoperative sinus tachycardia and hypertension; postoperative use such as in coarctation repair may be associated with with bradycardia or AV block; or proarrhythmia.
Dronedarone exhibited a favorable safety profile, most importantly with regard to its reassuringly low proarrhythmia potential.